Table 2.
Acute Stroke Care Metrics Among Different Racial‐Ethnic Subgroups in Florida and Puerto Rico, 2010–2014
| AOR (95% CI) | Florida | Puerto Rico | ||
|---|---|---|---|---|
| Non‐Hispanic White | Non‐Hispanic Black | Hispanic | Hispanic | |
| IV tPA, arrive by 2 hours and treat by 3 hours | ||||
| No. eligible | 2540 | 500 | 552 | 286 |
| Treated, % | 89 | 87 | 91 | 78 |
| AOR (95% CI) Model 1a | Ref | 0.96 (0.75–1.22) | 1.20 (0.90–1.58) | 0.22 (0.07–0.73) |
| AOR (95% CI) Model 2b | 0.92 (0.66–1.28) | 1.30 (0.90–1.89) | 0.72 (0.24–2.13) | |
| AOR (95% CI) Model 3c | 0.89 (0.63–1.26) | 1.30 (0.85–2.00) | 0.60 (0.21–1.72) | |
| Early antithrombotic use | ||||
| No. eligible | 24 813 | 7465 | 5488 | 2103 |
| Treated, % | 96 | 95 | 96 | 93 |
| AOR (95% CI) Model 1 | Ref | 0.91 (0.80–1.03) | 0.96 (0.73–1.27) | 0.13 (0.05–0.32) |
| AOR (95% CI) Model 2 | 0.94 (0.79–1.12) | 0.98 (0.69–1.38) | 0.37 (0.13–1.06) | |
| AOR (95% CI) Model 3 | 0.98 (0.84–1.14) | 1.01 (0.75–1.36) | 0.24 (0.10–0.55) | |
| Antithrombotics at discharge | ||||
| No. eligible | 25 689 | 7654 | 5621 | 2095 |
| Treated, % | 98 | 97 | 97 | 94 |
| AOR (95% CI) Model 1 | Ref | 0.92 (0.77–1.10) | 1.04 (0.60–1.80) | 0.10 (0.04–0.24) |
| AOR (95% CI) Model 2 | 0.97 (0.80–1.18) | 1.07 (0.67–1.69) | 0.20 (0.09–0.47) | |
| AOR (95% CI) Model 3 | 1.10 (1.02–1.18) | 1.08 (0.96–1.21) | 0.29 (0.12–0.74) | |
| Anticoagulation for atrial fibrillation | ||||
| No. eligible | 4765 | 601 | 793 | 275 |
| Treated, % | 96 | 97 | 94 | 90 |
| AOR (95% CI) Model 1 | Ref | 1.09 (0.76–1.56) | 0.93 (0.66–1.33) | 0.36 (0.11–1.14) |
| AOR (95% CI) Model 2 | 1.07 (0.68–1.68) | 0.90 (0.61–1.34) | 0.72 (0.26–2.02) | |
| AOR (95% CI) Model 3 | 1.06 (0.67–1.66) | 0.88 (0.59–1.30) | 0.67 (0.24–1.85) | |
| Smoking cessation counseling | ||||
| No. eligible | 4712 | 1524 | 869 | 190 |
| Treated, % | 97 | 96 | 95 | 93 |
| AOR (95% CI) Model 1 | Ref | 0.67 (0.55–0.82) | 0.86 (0.50–1.46) | 0.23 (0.06–0.92) |
| AOR (95% CI) Model 2 | 0.69 (0.55–0.86) | 0.89 (0.54–1.48) | 0.44 (0.12–1.60) | |
| AOR (95% CI) Model 3 | 0.68 (0.54–0.86) | 0.91 (0.54–1.53) | 0.44 (0.12–1.61) | |
| LDL ≥100 mg/dL or ND—Statin | ||||
| No. eligible | 19 965 | 5917 | 4428 | 1596 |
| Treated, % | 92 | 93 | 93 | 83 |
| AOR (95% CI) Model 1 | Ref | 1.02 (0.92–1.14) | 1.14 (0.86–1.51) | 0.15 (0.07–0.31) |
| AOR (95% CI) Model 2 | 1.06 (0.96–1.18) | 1.16 (0.87–1.54) | 0.19 (0.09–0.38) | |
| AOR (95% CI) Model 3 | 1.10 (0.99–1.22) | 1.19 (0.89–1.58) | 0.23 (0.12–0.47) | |
| VTE prophylaxis | ||||
| No. eligible | 29 315 | 8394 | 6416 | 2527 |
| Treated, % | 85 | 87 | 86 | 67 |
| AOR (95% CI) Model 1 | Ref | 1.06 (0.99–1.14) | 1.05 (0.95–1.16) | 0.24 (0.13–0.46) |
| AOR (95% CI) Model 2d | 1.08 (1.00–1.16) | 1.07 (0.95–1.20) | 0.25 (0.10–0.66) | |
| AOR (95% CI) Model 3 | 1.10 (1.02–1.18) | 1.08 (0.96–1.21) | 0.29 (0.12–0.74) | |
| Defect‐free care | ||||
| No. eligible | 29 865 | 8538 | 6529 | 2588 |
| Treated, % | 79 | 81 | 79 | 57 |
| AOR (95% CI) Model 1 | Ref | 1.10 (1.03–1.17) | 1.02 (0.96–1.09) | 0.35 (0.32–0.38) |
| AOR (95% CI) Model 2 | 1.06 (1.00–1.13) | 1.05 (0.95–1.16) | 0.26 (0.12–0.56) | |
| AOR (95% CI) Model 3 | 1.07 (1.00–1.14) | 1.06 (0.95–1.18) | 0.27 (0.12–0.58) | |
AOR indicates adjusted odds ratio; IV tPA, intravenous tissue plasminogen activator; LDL, low‐density lipoprotein; ND, not documented; VTE, venous thromboembolism.
Model 1 adjusted for age and correlation within and between hospitals.
Model 2 additionally adjusted for age, health insurance status, mode of arrival and hospital‐level factors including number of beds, years in Get With the Guidelines‐Stroke, and academic vs not.
Model 3 includes variables in model 2 and patient National Institutes of Health Stroke Scale score, current smoker, hypertension, diabetes, dyslipidemia, and medical history of atrial fibrillation, coronary artery disease/prior myocardial infarction, and previous stroke/transient ischemic attack.
In order for this model to converge, health insurance status was not included as a covariate.